Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)

NCT02551679 is registered in ClinicalTrials.gov with Hemostemix as lead sponsor.

NCT NCT02551679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02551679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)
Lead sponsor
Hemostemix
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2014
Completion date
April 30, 2021
Enrollment
67 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia